Clinical Trial Details
— Status: Recruiting
Administrative data
| NCT number |
NCT04051814 |
| Other study ID # |
191-18-CV |
| Secondary ID |
|
| Status |
Recruiting |
| Phase |
|
| First received |
|
| Last updated |
|
| Start date |
July 31, 2019 |
| Est. completion date |
May 15, 2025 |
Study information
| Verified date |
February 2023 |
| Source |
Hoag Memorial Hospital Presbyterian |
| Contact |
Leila Andres, MS |
| Phone |
949-764-4510 |
| Email |
clinicalresearch[@]hoag.org |
| Is FDA regulated |
No |
| Health authority |
|
| Study type |
Observational [Patient Registry]
|
Clinical Trial Summary
This is a retrospective study of our patient population implanted with the Medtronic's
Leadless single-chamber ventricular pacemakers.
Description:
This protocol outlines the methods on the Micra Pacemaker. The Micra Transcatheter Pacemaker
System is a miniaturized single chamber pacemaker system that is delivered via catheter
through the femoral vein and is implanted directly inside the right ventricle of the heart.
The Micra device eliminates the need for a device pocket and insertion of a pacing lead,
thereby eliminating lead and pocket related complications associated with traditional pacing
systems while providing similar pacing benefits. The US Food and Drug Administration (FDA)
approved the Micra system on April 6, 2016, for the following conditions:
- symptomatic paroxysmal or permanent high-grade atrioventricular block (AV) in the
presence of atrial fibrillation (AF)
- symptomatic paroxysmal or permanent high-grade AV block in the absence of AF, as an
alternative to dual chamber pacing, when atrial lead placement is considered difficult,
high risk, or not deemed necessary for effective therapy
- symptomatic bradycardia-tachycardia syndrome or sinus node dysfunction (sinus
bradycardia or sinus pauses), as an alternative to atrial or dual chamber pacing, when
atrial lead placement is considered difficult, high risk, or not deemed necessary for
effective therapy The FDA approved the Micra system on the basis of clinical trial
evidence from the Micra Investigational Device Exemption (IDE) study (NCT02488681).
On January 18, 2017, the Centers for Medicare and Medicaid Services (CMS) issued a final
National Coverage Determination (NCD) on leadless pacemakers, providing for coverage with
Coverage with Evidence Development (CED) of approved leadless pacemakers for approved
indications (CAG-00448N). The NCD requires the research study conducted as part of CED to
address the following research questions:
1. What are the peri-procedural and post-procedural complications of leadless pacemakers?
2. What are the long-term outcomes of leadless pacemakers?
3. What are the effects of patient characteristics (age, gender, comorbidities) on the use
and health effects of leadless pacemakers?
In addition, CMS outlined six evidentiary gaps in the final NCD for leadless pacemakers:
1. What are the peri-procedural and post-procedural complications, and long term outcomes
of leadless pacemakers?
2. Are leadless pacemakers equivalent or superior to conventional pacemaker's in general
clinical practice?
3. What are the infection rates, the long-term hemodynamic effects, and the rates of
formation of thrombi?
4. What are the patient demographics and effects of patient characteristics (age, gender,
comorbidities) on the use and health effects of leadless pacemakers?
5. What are the device-related issues (handling of end of battery life; effects of having
multiple leadless pacemakers implanted; rate of device dislodgement; and the possibility
of device extractions)?
6. How are operators and facility characteristics related to peri-procedural and
post-procedural complications?
